News | July 24, 2025
Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr
Revenue increased 11.4 per cent to Rs. 8,545 crore
Revenue increased 11.4 per cent to Rs. 8,545 crore
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Subscribe To Our Newsletter & Stay Updated
